| Schedule of Stock Option Activity |
A summary of the Plans’ stock option activity for the nine months ended September 30, 2026 and September 30, 2025 is presented below: | | | | | | | | | | | | | | | | | | | | | | | | | Stock Options | Common
Shares | | Weighted
Average
Strike Price | | Remaining Contractual Term (1) | | Intrinsic Value (2) (in thousands) | | Balance at December 31, 2025 | 5,675 | | | $ | 44.81 | | | | | | | | | | | | | | | Exercised | (2,325) | | | 40.97 | | | | | | | | | | | | | | Outstanding at September 30, 2026 | 3,350 | | | $ | 47.47 | | | 2.3 | | $ | 316 | | Exercisable at September 30, 2026 | 3,350 | | | $ | 47.47 | | | 2.3 | | $ | 316 | |
| | | | | | | | | | | | | | | | | | | | | | | | | Stock Options | Common
Shares | | Weighted
Average
Strike Price | | Remaining Contractual Term (1) | | Intrinsic Value (2) (in thousands) | | Balance at December 31, 2024 | 10,825 | | | $ | 43.76 | | | | | | | | | | | | | | | | | | | | | | | Exercised | (5,150) | | | 42.61 | | | | | | | | | | | | | | Outstanding at September 30, 2025 | 5,675 | | | $ | 44.81 | | | 3.0 | | $ | 497 | | Exercisable at September 30, 2025 | 5,675 | | | $ | 44.81 | | | 3.0 | | $ | 497 | |
(1)Represents the remaining weighted average contractual life in years. (2)Aggregate intrinsic value represents the total pre-tax intrinsic value (i.e., the difference between the Company’s stock price on the last trading day of the quarter and the option exercise price, multiplied by the number of shares) that would have been received by the option holders if they had exercised their options on the last day of the quarter. Options with exercise prices above the stock price on the last trading day of the quarter are excluded from the calculation of intrinsic value. The intrinsic value will change based on the fair market value of the Company’s stock.
|
| Schedule of Plans' Restricted and Performance Share Award Activity |
A summary of the Plans’ restricted share activity for the nine months ended September 30, 2026 and September 30, 2025 is presented below: | | | | | | | | | | | | | | | | | | | | | | | | | Nine months ended September 30, 2026 | | Nine months ended September 30, 2025 | | Restricted Shares | Common
Shares | | Weighted
Average
Grant-Date
Fair Value | | Common
Shares | | Weighted
Average
Grant-Date
Fair Value | | Outstanding at December 31 | 888,398 | | | $ | 101.63 | | | 880,866 | | | $ | 90.95 | | | Granted | 267,358 | | | 153.36 | | | 256,762 | | | 133.15 | | | Vested and issued | (289,049) | | | 93.58 | | | (218,276) | | | 94.41 | | | Forfeited or canceled | (30,623) | | | 126.66 | | | (24,156) | | | 109.48 | | Outstanding at September 30 | 836,084 | | | $ | 120.23 | | | 895,196 | | | $ | 101.71 | | Vested, but deferred, at September 30 | 103,330 | | | $ | 56.63 | | | 101,820 | | | $ | 55.31 | |
A summary of the Plans’ performance-based stock award activity, based on the target level of the awards, for the nine months ended September 30, 2026 and September 30, 2025 is presented below: | | | | | | | | | | | | | | | | | | | | | | | | | Nine months ended September 30, 2026 | | Nine months ended September 30, 2025 | | Performance-based Stock | Common
Shares | | Weighted
Average
Grant-Date
Fair Value | | Common
Shares | | Weighted
Average
Grant-Date
Fair Value | | Outstanding at December 31 | 377,757 | | | $ | 102.38 | | | 454,017 | | | $ | 93.57 | | | Granted | 86,224 | | | 148.35 | | | 88,257 | | | 134.58 | | | Added by performance factor at vesting, net | 9,242 | | | — | | | 75,461 | | | — | | | Vested and issued | (196,899) | | | 90.33 | | | (230,957) | | | 95.26 | | | Forfeited or canceled | (2,576) | | | 121.03 | | | (8,218) | | | 107.24 | | Outstanding at September 30 | 273,748 | | | $ | 125.98 | | | 378,560 | | | $ | 102.35 | | Vested, but deferred, at September 30 | — | | | $ | — | | | 13,283 | | | $ | 40.87 | |
|